SCHEMBL4059930

SCHEMBL4059930

CCCOc1cccc(-c2nc3ncc(-c4ccccc4F)cc3[nH]2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 2/20 0.50
AURKA O14965 4/20 0.44
CYP3A4 P08684 1/20 0.43
PDE5A O76074 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
BRAF P15056 2/20 0.42
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HDAC3 O15379 5/20 0.40
HDAC4 P56524 5/20 0.40
HDAC1 Q13547 5/20 0.40
HDAC7 Q8WUI4 5/20 0.40
HDAC2 Q92769 5/20 0.40
HDAC10 Q969S8 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057675 0.95 SCD (0.49) SCDAURKACYP3A4PDE5APDE4A
SCHEMBL4051568 0.93 SCD (0.48) SCDAURKACYP3A4PDE5APDE4A
SCHEMBL4049461 0.92 SCD (0.52) SCDAURKACYP3A4PDE5ABRAF
SCHEMBL4239962 0.89 SCD (0.48) SCDAURKACYP3A4BRAFHDAC3
SCHEMBL4053057 0.88 AURKA (0.50) AURKAMAPTTP53SMN1; SMN2MEN1
SCHEMBL4234520 0.88 SCD (0.46) SCDAURKACYP3A4HDAC3HDAC4
SCHEMBL4060707 0.87 SCD (0.49) SCDAURKACYP3A4BRAFFGFR1
SCHEMBL4226507 0.86 SCD (0.48) SCDAURKACYP3A4BRAFHDAC3
SCHEMBL4054757 0.85 SCD (0.50) SCDAURKACYP3A4BRAFGSK3A
SCHEMBL4056658 0.85 SCD (0.51) SCDAURKACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B SCD 4559/4885AURKA 247/4885CYP3A4 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.